TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Cluster Randomised Trial Comparing the Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence. The ARNS 12249 TasP (Treatment as Prevention) Trial in Hlabisa Sub-district, KwaZulu-Natal, South Africa.
Brief Summary: This trial is evaluating a public health intervention strategy trial which aims to reduce the incidence of HIV at a population-level.

The proposed strategy is a two steps process:

* Extensive HIV counselling and testing, and comprehensive prevention programme among a target population
* Immediate ART initiation after HIV diagnosis, irrespective of CD4 count criteria.

The underlaying trial hypothesis is that HIV testing followed by immediate ART initiation of all HIV-infected individuals will prevent onward transmission and reduce HIV incidence in the population. This is a cluster randomised controlled trial with a total of 22 communities used as the units for randomisation. Enrolment of a population of 22 000 individuals among which 4 400 are expected to be HIV-Infected.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, lamivudine and Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Fluconazole, Drug: Fixed dose - Stavudine, Lamivudine, Nevirapine | Intervention Type: DRUG; Name: Fluconazole; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, lamivudine and Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Fixed dose - Stavudine, Lamivudine, Nevirapine; Assigned to Arm(s): 2
B: Arm Label: Standard; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: SLATE | Intervention Type: OTHER; Name: SLATE; Assigned to Arm(s): Intervention
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Efavirenz, Drug: Lamivudine/Zidovudine | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Efavirenz, Drug: Lamivudine/Zidovudine | Intervention Type: DRUG; Name: Efavirenz; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: Lamivudine/Zidovudine; Assigned to Arm(s): A, B
D: Arm Label: Immediate ARV treatment initiation; Type: EXPERIMENTAL; Interventions: Drug: Immediate ARV treatment initiation with TDF/FTC/EFV | Arm Label: South African recommendation guided ARV initiation; Type: OTHER; Interventions: Other: South African recommendation guided ARV (TDF/FTC/EFV) initiation | Intervention Type: DRUG; Name: Immediate ARV treatment initiation with TDF/FTC/EFV; Assigned to Arm(s): Immediate ARV treatment initiation | Intervention Type: OTHER; Name: South African recommendation guided ARV (TDF/FTC/EFV) initiation; Assigned to Arm(s): South African recommendation guided ARV initiation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Oxygenation of the Brain During Caesarean Section. A Comparison of Ephedrine Versus Phenylephrine
Brief Summary: The purpose of this study is to determine the impact of phenylephrine versus ephedrine on organ perfusion, in women undergoing caesarean section receiving spinal anaesthesia. The organ perfusion is estimated by measuring the maternal cerebral oxygenation by NIRS(Near-infrared spectroscopy)and the foetal heartrate.


Options:
A: Arm Label: ondansetron; Type: EXPERIMENTAL; Interventions: Drug: ondansetron | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: ondansetron; Assigned to Arm(s): ondansetron | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Phenylephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenylephrine | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Ephedrine | Intervention Type: DRUG; Name: Phenylephrine; Assigned to Arm(s): Phenylephrine
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: HES 130/0.4 (6%) in sodium chloride (solution for infusion) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringer's Lactate solution | Intervention Type: DRUG; Name: HES 130/0.4 (6%) in sodium chloride (solution for infusion); Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Ringer's Lactate solution; Assigned to Arm(s): Group B
D: Arm Label: 2 ml bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2 ml bupivacaine | Arm Label: 1.5 ml bupivicaine.; Type: ACTIVE_COMPARATOR; Interventions: Drug: 1.5 ml bupivicaine. | Intervention Type: DRUG; Name: 2 ml bupivacaine; Assigned to Arm(s): 2 ml bupivacaine | Intervention Type: DRUG; Name: 1.5 ml bupivicaine.; Assigned to Arm(s): 1.5 ml bupivicaine.

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Oxygenation of the Brain During Caesarean Section. A Comparison of Ephedrine Versus Phenylephrine
Brief Summary: The purpose of this study is to determine the impact of phenylephrine versus ephedrine on organ perfusion, in women undergoing caesarean section receiving spinal anaesthesia. The organ perfusion is estimated by measuring the maternal cerebral oxygenation by NIRS(Near-infrared spectroscopy)and the foetal heartrate.


Options:
A: Arm Label: Prophylactic ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Normal saline (placebo) control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Prophylactic ephedrine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Normal saline (placebo) control group
B: Arm Label: 2 ml bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: 2 ml bupivacaine | Arm Label: 1.5 ml bupivicaine.; Type: ACTIVE_COMPARATOR; Interventions: Drug: 1.5 ml bupivicaine. | Intervention Type: DRUG; Name: 2 ml bupivacaine; Assigned to Arm(s): 2 ml bupivacaine | Intervention Type: DRUG; Name: 1.5 ml bupivicaine.; Assigned to Arm(s): 1.5 ml bupivicaine.
C: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Drug: HES 130/0.4 (6%) in sodium chloride (solution for infusion) | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ringer's Lactate solution | Intervention Type: DRUG; Name: HES 130/0.4 (6%) in sodium chloride (solution for infusion); Assigned to Arm(s): Group A | Intervention Type: DRUG; Name: Ringer's Lactate solution; Assigned to Arm(s): Group B
D: Arm Label: Ephedrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ephedrine | Arm Label: Phenylephrine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenylephrine | Intervention Type: DRUG; Name: Ephedrine; Assigned to Arm(s): Ephedrine | Intervention Type: DRUG; Name: Phenylephrine; Assigned to Arm(s): Phenylephrine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation
Brief Summary: This is a placebo-controlled smoking cessation treatment study for adolescents ages 14-21. After assessment and inclusion into the study, participants will be randomized to receive a 12-week double blind course of varenicline or placebo.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: Cytisine plus behavioural support; Type: EXPERIMENTAL; Interventions: Drug: Cytisine, Behavioral: Behavioural support | Arm Label: Varenicline plus behavioural support; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioural support, Drug: Varenicline | Intervention Type: DRUG; Name: Cytisine; Assigned to Arm(s): Cytisine plus behavioural support | Intervention Type: BEHAVIORAL; Name: Behavioural support; Assigned to Arm(s): Cytisine plus behavioural support, Varenicline plus behavioural support | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline plus behavioural support
C: Arm Label: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Placebo, Varenicline
D: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Varenicline for Adolescent Smoking Cessation
Brief Summary: This is a placebo-controlled smoking cessation treatment study for adolescents ages 14-21. After assessment and inclusion into the study, participants will be randomized to receive a 12-week double blind course of varenicline or placebo.


Options:
A: Arm Label: Varenicline and Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline and Placebo Patch | Arm Label: Varenicline and Nicotine Patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Nicotine Patch | Intervention Type: DRUG; Name: Varenicline, Nicotine Patch; Assigned to Arm(s): Varenicline and Nicotine Patch | Intervention Type: DRUG; Name: Varenicline and Placebo Patch; Assigned to Arm(s): Varenicline and Placebo Patch
B: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Arm Label: High-intensity group; Type: EXPERIMENTAL; Interventions: Other: High-intensity smoking cessation intervention | Arm Label: Low-intensity group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Low-intensity smoking cessation intervention | Intervention Type: OTHER; Name: High-intensity smoking cessation intervention; Assigned to Arm(s): High-intensity group | Intervention Type: DRUG; Name: Low-intensity smoking cessation intervention; Assigned to Arm(s): Low-intensity group
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation | Arm Label: Simultaneous; Type: EXPERIMENTAL; Interventions: Behavioral: Weight gain prevention and smoking cessation | Arm Label: Sequential; Type: EXPERIMENTAL; Interventions: Behavioral: Weight gain prevention and smoking cessation | Intervention Type: BEHAVIORAL; Name: Weight gain prevention and smoking cessation; Assigned to Arm(s): Sequential, Simultaneous | Intervention Type: BEHAVIORAL; Name: Smoking cessation; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family-Based Prevention of Mental Health Problems in HIV/AIDS-Affected Children (R34MH084679-01A1)
Brief Summary: The research will examine the following Specific Aims:

Specific Aim 1: To adapt a U.S.-developed family-focused and strengths-based prevention program to the context of HIV/AIDS-affected families in Rwanda (the Family-Strengthening Intervention in Rwanda or "FSI-R") using prior qualitative findings and CAB input.

Specific Aim 2: To deliver the intervention to a small group of families to collect preliminary data on intervention feasibility, acceptability, and to further refine the intervention manual for the FSI-R.

Specific Aim 3: To conduct a pilot feasibility study of the FSI-R with 80 families.

In pursuit of Specific Aim 3, this research will (a) conduct a preliminary exploratory analysis to examine the extent to which the FSI-R for HIV/AIDS-affected families is associated with improved caregiver-child relationships using measures of family connectedness, good parenting, and social support. Hypothesis 1: Participants in the FSI-R will demonstrate increases in protective processes compared to usual care controls not exposed to the FSI-R. It will also (b) conduct a preliminary exploratory analysis to determine the extent to which improved caregiver-child relationships are sustained four months after the conclusion of the FSI-R. Hypothesis 2: Four months after the conclusion of the intervention, participants in the FSI-R will demonstrate increases in protective processes compared to usual care controls not exposed to the FSI-R.


Options:
A: Arm Label: mSBIRT; Type: EXPERIMENTAL; Interventions: Behavioral: Screening, Brief Intervention, Referral to Treatment | Arm Label: SBIRT-CTS),; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Screening, Brief Intervention, Referral to Treatment | Intervention Type: BEHAVIORAL; Name: Screening, Brief Intervention, Referral to Treatment; Assigned to Arm(s): SBIRT-CTS),, mSBIRT
B: Arm Label: FSI-R (Intervention group); Type: EXPERIMENTAL; Interventions: Behavioral: Family Strengthening Intervention in Rwanda (FSI-R) | Arm Label: TAU (Treatment as Usual); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Family Strengthening Intervention in Rwanda (FSI-R); Assigned to Arm(s): FSI-R (Intervention group)
C: Arm Label: "Parents Make the Difference"; Type: EXPERIMENTAL; Interventions: Behavioral: Parents Make the Difference | Arm Label: Waitlist Control; Type: OTHER; Interventions: Behavioral: Parents Make the Difference | Intervention Type: BEHAVIORAL; Name: Parents Make the Difference; Assigned to Arm(s): "Parents Make the Difference", Waitlist Control
D: Arm Label: Obese patients treated with bariatric surgery; Type: EXPERIMENTAL; Interventions: Procedure: Bariatric surgery | Arm Label: Obese patients not treated with bariatric surgery; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Bariatric surgery; Assigned to Arm(s): Obese patients treated with bariatric surgery

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Pain Relief Trial Utilizing the Infiltration of a Multivesicular Liposome Formulation Of Bupivacaine, EXPAREL®: A Phase 4 Health Economic Trial in Adult Patients Undergoing Ileostomy Reversal
Brief Summary: This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.


Options:
A: Arm Label: Bupivacaine and low dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: Bupivacaine and high dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: Bupivacaine; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Arm Label: High dose SKY0402; Type: N/A; Interventions: Drug: Questionnaire and Physical Exam | Intervention Type: DRUG; Name: Questionnaire and Physical Exam; Assigned to Arm(s): Bupivacaine, Bupivacaine and high dose SKY0402, Bupivacaine and low dose SKY0402, High dose SKY0402
B: Arm Label: Morphine sulfate; Type: ACTIVE_COMPARATOR; Interventions: Drug: morphine sulfate | Arm Label: EXPAREL; Type: EXPERIMENTAL; Interventions: Drug: bupivacaine liposome extended-release injectable suspension | Intervention Type: DRUG; Name: morphine sulfate; Assigned to Arm(s): Morphine sulfate | Intervention Type: DRUG; Name: bupivacaine liposome extended-release injectable suspension; Assigned to Arm(s): EXPAREL
C: Arm Label: Group 1 Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Group 1 Standard of Care | Arm Label: Group 2 EXPAREL; Type: ACTIVE_COMPARATOR; Interventions: Drug: Group 2 EXPAREL | Intervention Type: DRUG; Name: Group 1 Standard of Care; Assigned to Arm(s): Group 1 Standard of Care | Intervention Type: DRUG; Name: Group 2 EXPAREL; Assigned to Arm(s): Group 2 EXPAREL
D: Arm Label: SKY0402; Type: EXPERIMENTAL; Interventions: Drug: SKY0402 | Arm Label: Bupivacaine HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine HCl | Intervention Type: DRUG; Name: SKY0402; Assigned to Arm(s): SKY0402 | Intervention Type: DRUG; Name: Bupivacaine HCl; Assigned to Arm(s): Bupivacaine HCl

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 16-week, Randomized, Placebo-controlled, Double Blind, and Parallel Group Trial to Assess the Anti-inflammatory Effects of Roflumilast in Chronic Obstructive Pulmonary Disease
Brief Summary: The objective of the Biopsy trial is to investigate the effect of roflumilast 500 µg tablets once daily versus placebo on inflammation parameters in bronchial biopsy tissue specimen and additional in sputum and blood serum. Also data on safety status will be obtained.

Patients to be included required to have moderate to severe COPD associated with chronic bronchitis. The total duration of this randomized, multicentre, phase III trial is 24 weeks maximum.


Options:
A: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
D: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled, Combination Study to Evaluate the Efficacy and Safety of Lesinurad and Allopurinol Compared to Allopurinol Alone in Subjects With Gout Who Have Had an Inadequate Hypouricemic Response to Standard of Care Allopurinol.
Brief Summary: This study that compare the serum uric acid lowering effects, clinical benefits, and safety of lesinurad in combination with allopurinol to allopurinol alone in subjects with gout who have had an inadequate response to allopurinol.


Options:
A: Arm Label: Nurse intervention; Type: OTHER; Interventions: Other: Nurse intervention | Arm Label: Standard care; Type: OTHER; Interventions: Other: Standard care | Intervention Type: OTHER; Name: Nurse intervention; Assigned to Arm(s): Nurse intervention | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard care
B: Arm Label: Febuxostat; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol
C: Arm Label: lesinurad 200 mg + allopurinol; Type: EXPERIMENTAL; Interventions: Drug: Lesinurad, Drug: Allopurinol | Arm Label: lesinurad 400 mg + allopurinol; Type: EXPERIMENTAL; Interventions: Drug: Lesinurad, Drug: Allopurinol | Arm Label: Placebo + allopurinol; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Allopurinol | Intervention Type: DRUG; Name: Lesinurad; Assigned to Arm(s): lesinurad 200 mg + allopurinol | Intervention Type: DRUG; Name: Lesinurad; Assigned to Arm(s): lesinurad 400 mg + allopurinol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + allopurinol | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): lesinurad 200 mg + allopurinol | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): lesinurad 400 mg + allopurinol | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Placebo + allopurinol
D: Arm Label: q2 wks; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: q4 wks; Type: EXPERIMENTAL; Interventions: Biological: pegloticase | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: BIOLOGICAL; Name: pegloticase; Assigned to Arm(s): q2 wks, q4 wks

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Milnacipran for the Pain, Sensory Sensitization and Mood Changes in Knee Osteoarthritis
Brief Summary: The patients are asked to take part in this study because you have chronic pain as a result of knee osteoarthritis. This study is done to investigate the pain relieving effects of the study drug Savella (milnacipran HCl) for people who experience chronic osteoarthritis pain. The purpose of this research is to look at how the study drug can be used to benefit people who experience osteoarthritis knee pain. This is a phase IV study done to study the safety and effectiveness of the drug. At this point the drug is already approved by the Food and Drug Administration for people with fibromyalgia but it has not yet been approved for people with knee osteoarthritis.


Options:
A: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Placebo Oral Tablet | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Placebo Oral Tablet; Assigned to Arm(s): Placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar Pill
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: C